FOR IMMEDIATE RELEASE
November 18, 2026
CONTACT: Kyra Smith
Washington, D.C.—U.S. Senator Mike Crapo (R-Idaho) joined Senate Judiciary Committee Chairman Chuck Grassley (R-Iowa) and six Republican Senators in a letter urging the Drug Enforcement Administration (DEA) and the Food and Drug Administration (FDA) to explain and reconsider proposed changes to the emergency scheduling order for semi-synthetic, kratom-derived substances, including 7-hydroxymitragynine (7-OH) and mitragynine pseudoindoxyl (MP).
In July 2026, the DEA proposed placing 7-OH above a 0.05 percent threshold in Schedule I of the Controlled Substances Act and subsequently issued an order placing three semi-synthetic kratom-related substances, including MP, in Schedule I. However, in October, the DEA reversed course, issuing a revised proposal that doubled the original threshold established for 7-OH and removed MP from Schedule I. October’s decision would allow both chemicals to be present in over-the-counter kratom products at levels higher than those found naturally in the kratom plant.
“Kratom is a drug in any form with addictive properties, and we believe this combined threshold level for 7-OH and MP set by DEA is inappropriately high and unsound… If the administration’s goal is to remove all unsafe products from the shelves, particularly synthetic or enhanced kratom products, this order misses the mark,” the lawmakers wrote.
“The psychoactive alkaloids of the kratom plant are potentially dangerous substances that should be treated with caution, particularly given the lack of adequate regulation on its products… The American people deserve peace of mind about what is sold on marketplace shelves and a public health system that makes sound regulatory decisions,” the lawmakers continued.
Specifically, the Senators’ letter requests the DEA and FDA:
- Provide Congress the scientific and medical evaluations the agencies relied on to set a higher threshold limit for 7-OH;
- Explain how a higher threshold for 7-OH better protects American families than the original, lower threshold; and
- Reconsider the updated threshold level for 7-OH and place kratom substances containing any amount of MP in Schedule I.
Crapo and Grassley are joined on the letter by Senators Jim Risch (R-Idaho), Susan Collins (R-Maine), Rick Scott (R-Florida), Bill Cassidy (R-Louisiana), Jerry Moran (R-Kansas) and Shelley Moore Capito (R-West Virginia).
Read the full letter here. A fact sheet on kratom and the timeline for DEA’s proposed scheduling order is available here.
Background
Kratom leaves contain two major psychoactive ingredients: mitragynine and 7-hydroxymitragynine (7-OH). These substances can be concentrated and chemically modified to produce extremely potent, semi-synthetic compounds – MP, MGM-15 and MGM-16. Kratom and kratom-derived substances are sold over the counter across the country, available to all age groups as “natural” energy boosters, mood lifters and pain relievers.
According to the FDA, known side effects of kratom include liver toxicity, seizures, substance use disorder and, in rare cases, death. The Idaho Department of Health and Welfare reported 83 deaths from kratom-related overdoses from 2020 to 2024. In November 2025, Bonneville County reported six deaths in 18 months. According to the DEA, state health authorities have linked the use of 7-OH products and concentrated extracts to dependence, addiction, acute psychosis, slowed breathing, cardiac arrest and death.
Kratom-derived 7-OH has been identified as having a similar abuse potential to heroin or fentanyl and is known to be 13-times more potent than morphine. Other kratom-derived compounds, like MP, are known to be 20-times more potent than morphine.
The Gem State Chronicle delivers daily analysis, op-eds, press releases, and Idaho Insider updates—free to your inbox.
Free newsletter · Unsubscribe anytime
About Mike Crapo
Senator Mike Crapo has represented Idaho in the Senate since 1999, following three terms in the U.S. House and eight years in the Idaho State Senate. A lifelong Idahoan, he currently serves as Chairman of the Senate Finance Committee.






